Axsome Therapeutics Inc (NASDAQ:AXSM) shares hit a new 52-week high on Thursday . The stock traded as high as $10.89 and last traded at $10.69, with a volume of 33659 shares. The stock had previously closed at $10.42.
Several analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of Axsome Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, January 14th. ValuEngine downgraded shares of Axsome Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 21st. HC Wainwright set a $15.00 price objective on shares of Axsome Therapeutics and gave the company a “buy” rating in a research report on Tuesday, March 5th. LADENBURG THALM/SH SH reaffirmed a “positive” rating and set a $45.00 price objective (up from $34.00) on shares of Axsome Therapeutics in a research report on Monday, January 7th. Finally, Cantor Fitzgerald began coverage on shares of Axsome Therapeutics in a research note on Thursday, November 15th. They issued an “overweight” rating and a $16.00 target price for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $24.00.
The company has a market capitalization of $302.90 million, a PE ratio of -8.64 and a beta of 3.32. The company has a debt-to-equity ratio of 6.00, a current ratio of 1.46 and a quick ratio of 1.46.
About Axsome Therapeutics (NASDAQ:AXSM)
Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation.
Featured Story: What is the downside to momentum investing?
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.